Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 3
1992 4
1993 1
1994 4
1996 4
1997 3
1998 5
1999 3
2000 4
2001 3
2002 9
2003 6
2004 12
2005 11
2006 19
2007 13
2008 12
2009 13
2010 17
2011 19
2012 11
2013 15
2014 24
2015 19
2016 26
2017 31
2018 25
2019 20
2020 28
2021 16
2022 11
2023 3
Text availability
Article attribute
Article type
Publication date

Search Results

344 results
Results by year
Filters applied: . Clear all
Page 1
Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).
Lebwohl M, Kircik L, Lacour JP, Liljedahl M, Lynde C, Mørch MH, Papp KA, Perrot JL, Gold LS, Takhar A, Thaçi D, Warren RB, Wollenberg A. Lebwohl M, et al. J Am Acad Dermatol. 2021 May;84(5):1269-1277. doi: 10.1016/j.jaad.2020.09.037. Epub 2020 Sep 18. J Am Acad Dermatol. 2021. PMID: 32950546 Free article. Clinical Trial.
OBJECTIVE: Assess long-term efficacy and safety of proactive psoriasis management with twice-weekly calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam. ...
OBJECTIVE: Assess long-term efficacy and safety of proactive psoriasis management with twice-weekly calcipotriene 0.005%/betamethason …
Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis.
Kin KC, Hill D, Feldman SR. Kin KC, et al. Expert Rev Clin Pharmacol. 2016 Jun;9(6):789-97. doi: 10.1080/17512433.2016.1179574. Epub 2016 May 13. Expert Rev Clin Pharmacol. 2016. PMID: 27089906 Review.
Topical treatments are the mainstay of treatment. AREAS COVERED: Two-compound calcipotriene and betamethasone dipropionate (BD) is a common topical combination therapy consisting of a vitamin D analogue and a corticosteroid. ...Topical scalp solution was also safe and effe …
Topical treatments are the mainstay of treatment. AREAS COVERED: Two-compound calcipotriene and betamethasone dipropionate (BD) is a …
Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis.
Amat-Samaranch V, Puig L. Amat-Samaranch V, et al. Expert Opin Drug Saf. 2020 Apr;19(4):423-432. doi: 10.1080/14740338.2020.1749594. Epub 2020 Apr 13. Expert Opin Drug Saf. 2020. PMID: 32243212 Review.
Most patients have mild disease that is usually controlled with topical treatment. Calcipotriene 0.05% and betamethasone dipropionate 0.064% (Cal/BD) in aerosol foam (Enstilar) is a novel formulation, which has shown promising results in terms of efficacy and safety.Areas …
Most patients have mild disease that is usually controlled with topical treatment. Calcipotriene 0.05% and betamethasone dipropionate …
Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.
McCormack PL. McCormack PL. Am J Clin Dermatol. 2011 Dec 1;12(6):421-4. doi: 10.2165/11207670-000000000-00000. Am J Clin Dermatol. 2011. PMID: 21967117 Review.
Calcipotriene (calcipotriol)/betamethasone dipropionate (calcipotriene 50 mug/g and betamethasone 0.5 mg/g) is a fixed-dose combination of a vitamin D3 analog and a corticosteroid indicated for the once-daily, topical treatment of psoriasis vulgaris of the tr
Calcipotriene (calcipotriol)/betamethasone dipropionate (calcipotriene 50 mug/g and betamethasone 0.5 mg/g) is a fixed-
Fixed Combination Calcipotriene and Betamethasone Dipropionate (Cal/BD) Foam for Beyond-Mild Psoriasis: A Possible Alternative to Systemic Medication.
Kircik L, Stein Gold L, Teng J, Moore A, Cantrell W, Alonso-Llamazares J, Koo J. Kircik L, et al. J Drugs Dermatol. 2020 Aug 1;19(8):723-732. doi: 10.36849/JDD.2020.5300. J Drugs Dermatol. 2020. PMID: 32845591 Review.
Calcipotriene 0.005% plus betamethasone dipropionate 0.064% (Cal/BD) aerosol foam is a topical agent indicated for the treatment of plaque psoriasis. While topical treatments are typically reserved for milder disease, in clinical trials with Cal/BD foam, the vast majority
Calcipotriene 0.005% plus betamethasone dipropionate 0.064% (Cal/BD) aerosol foam is a topical agent indicated for the treatment of p
Calcipotriene/betamethasone in the treatment of psoriasis: a review article.
Saraceno R, Gramiccia T, Frascione P, Chimenti S. Saraceno R, et al. Expert Opin Pharmacother. 2009 Oct;10(14):2357-65. doi: 10.1517/14656560903198960. Expert Opin Pharmacother. 2009. PMID: 19663634 Review.
Optimization of these treatments is made by the combination of calcipotriene and betamethasone dipropionate. This formulation combines the keratinocyte differentiation and antiproliferative action of the vitamin D(3) analogues with the anti-inflammatory effect of steroids …
Optimization of these treatments is made by the combination of calcipotriene and betamethasone dipropionate. This formulation combine …
Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature.
Frieder J, Kivelevitch D, Menter A. Frieder J, et al. Ther Deliv. 2017 Aug;8(9):737-746. doi: 10.4155/tde-2017-0058. Epub 2017 Jun 29. Ther Deliv. 2017. PMID: 28659016 Review.
Mainstay topical treatments include corticosteroids and vitamin D derivatives. Calcipotriene/betamethasone dipropionate aerosol foam is a novel single product combination, which seeks to provide superior therapeutic efficacy in addition to enhanced cosmetic properti …
Mainstay topical treatments include corticosteroids and vitamin D derivatives. Calcipotriene/betamethasone dipropionate aerosol foam …
The two-compound formulation of calcipotriol and betamethasone dipropionate for treatment of moderately severe body and scalp psoriasis - an introduction.
Freeman K. Freeman K. Curr Med Res Opin. 2011 Jan;27(1):197-203. doi: 10.1185/03007995.2010.540985. Epub 2010 Dec 13. Curr Med Res Opin. 2011. PMID: 21142834
In the following in-journal supplement, a connected suite of five papers focus on the use of topical therapies for the treatment of the person afflicted with psoriasis. ...Based upon systematic review and harnessing 'state of the art' evidence assessment methodologies, the …
In the following in-journal supplement, a connected suite of five papers focus on the use of topical therapies for the treatment of t …
Scalp psoriasis.
Kircik LH, Kumar S. Kircik LH, et al. J Drugs Dermatol. 2010 Aug;9(8 Suppl ODAC Conf Pt 2):s101-5. J Drugs Dermatol. 2010. PMID: 20715392 Review.
This article aims to review the efficacy and safety of new formulations and treatment options available to control scalp psoriasis. For example, a new formulation of calcipotriene/betamethasone scalp solution has a rapid onset of action with once daily dosing that improves …
This article aims to review the efficacy and safety of new formulations and treatment options available to control scalp psoriasis. For exam …
Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years.
Eichenfield LF, Ganslandt C, Kurvits M, Schlessinger J. Eichenfield LF, et al. Pediatr Dermatol. 2015 Jan-Feb;32(1):28-35. doi: 10.1111/pde.12429. Epub 2014 Nov 21. Pediatr Dermatol. 2015. PMID: 25412565 Free PMC article. Clinical Trial.
The objective of this study was to assess the safety and efficacy of the fixed combination calcipotriene 0.005% plus betamethasone dipropionate 0.064% topical suspension in adolescents with extensive scalp psoriasis. ...By week 8, 28 patients (90%) experienced mild or no i …
The objective of this study was to assess the safety and efficacy of the fixed combination calcipotriene 0.005% plus betamethasone di …
344 results